Immune checkpoint blockade has redefined the treatment of gastro-oesophageal cancer, across the spectrum of neoadjuvant, adjuvant and metastatic settings. Immunotherapy is now embedded in first-line treatment for metastatic gastro-oesophageal cancer, with higher benefits seen in biomarker enriched populations. It has also being investigated in combination with Her-2 targeting agents, and being explored in combination with targeted agents which are emerging, such as agents targeting Claudin18.2 and FGFR2. Adjuvant immunotherapy has also become standard of care in patients with locally advanced disease who do not achieve a complete pathological response to neoadjuvant chemoradiation. The role of immunotherapy in the neoadjuvant setting is evolving, shifting the treatment landscape, and will likely change the paradigm of treatment. Newer agents such as Fc-engineered antibodies, bispecifics, and cell therapies are being investigated to overcome resistance mechanisms to immunotherapy.